Nuvisan
Business Services · Germany · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Wegenerstraße 13, Neu-Ulm, Bavaria, 8923...Phone Number
+49 230993760Website
www.nuvisan.comRevenue
$141.8 MillionIndustry
About Nuvisan
Nuvisan Org Chart
Is Nuvisan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Nuvisan recently announced quarterly report
Check out if Nuvisan is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Nuvisan
Funding: Get notified immidiatlly once Nuvisan has new funding data
Product Launch: Get notified when Nuvisan launches new products
Click to see if Nuvisan had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Nuvisan, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Nuvisan has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Nuvisan as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Nuvisan is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nuvisan is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nuvisan.
Nuvisan Tech Stack
A closer look at the technologies used by Nuvisan
Most Recent Scoops
Nuvisan News & Media
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture...ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement
DUBLIN & BERLIN--(BUSINESS WIRE)--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. NUVISAN ICB originated from aTHE NUVISAN GROUP Continues Its Growth by Adding Parts of the GALDERMA R&D Capabilities from NESTLÉ SKIN HEALTH
NEU-ULM, Germany--(BUSINESS WIRE)--#CRO--On August 31st the NUVISAN GROUP, one of Europe´s leading CRO´s focused on early stage drug development for the life science industry, signed an agreement with NESTLÉ SKIN HEALTH/ GALDERMA to take over parts of the R&D capacities in Sophia-Antipolis, France. The GALDERMA R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities wi
Top Business Services Companies
Frequently Asked Questions Regarding Nuvisan
Nuvisan is a German based pharmaceutical company that focuses on laboratory and clinical services, as well as offering integrated services in program solution or stand-alone solution. They were founded in 1979.... Read More